Abstract
Modafinil (MOD) it has to be considered as a wake-inducing drug to treat sleep disorders such as excessive sleepiness in narcolepsy, shift-work disorder, and obstructive/sleep apnea syndrome. Current evidence suggests that MOD induces waking involving the dopamine D1 receptor. However, little is known regarding the molecular elements linked in the wake-promoting actions of MOD. Since the D1 receptor activates the mitogen-activated protein kinase (MAP-K) cascade, it raises the interesting possibility that effects of MOD would depend upon the activation of MAP-K. Here we tested the expression of MAP-K in hypothalamus as well as pons after the microinjection of MOD (10 or 20μg/1μL) in rats into anterior hypothalamus, a wake-inducing brain area. Intrahypothalamic injections of MOD promoted MAP-K phosphorylation in hypothalamus and pons. Taken together, these results suggest that the wake-inducing compound MOD promotes the MAP-K phosphorylation.
Keywords: Dopamine, hypothalamus, modafinil, narcolepsy, protein, pons, rat, wakefulness, western blot.
CNS & Neurological Disorders - Drug Targets
Title:Intrahypothalamic Administration of Modafinil Increases Expression of MAP-Kinase in Hypothalamus and Pons in Rats
Volume: 14 Issue: 4
Author(s): Alwin Poot-Ake, Stephanie Mijangos-Moreno, Danielle Manjarrez-Martin, Ramses Jimenez-Moreno, Pedro R. Aquino-Hernandez, Elda Pacheco-Pantoja, Oscar Arias-Carrion, Andrea Sarro-Ramirez, Gloria Arankowsky-Sandoval and Eric Murillo-Rodriguez
Affiliation:
Keywords: Dopamine, hypothalamus, modafinil, narcolepsy, protein, pons, rat, wakefulness, western blot.
Abstract: Modafinil (MOD) it has to be considered as a wake-inducing drug to treat sleep disorders such as excessive sleepiness in narcolepsy, shift-work disorder, and obstructive/sleep apnea syndrome. Current evidence suggests that MOD induces waking involving the dopamine D1 receptor. However, little is known regarding the molecular elements linked in the wake-promoting actions of MOD. Since the D1 receptor activates the mitogen-activated protein kinase (MAP-K) cascade, it raises the interesting possibility that effects of MOD would depend upon the activation of MAP-K. Here we tested the expression of MAP-K in hypothalamus as well as pons after the microinjection of MOD (10 or 20μg/1μL) in rats into anterior hypothalamus, a wake-inducing brain area. Intrahypothalamic injections of MOD promoted MAP-K phosphorylation in hypothalamus and pons. Taken together, these results suggest that the wake-inducing compound MOD promotes the MAP-K phosphorylation.
Export Options
About this article
Cite this article as:
Poot-Ake Alwin, Mijangos-Moreno Stephanie, Manjarrez-Martin Danielle, Jimenez-Moreno Ramses, Aquino-Hernandez R. Pedro, Pacheco-Pantoja Elda, Arias-Carrion Oscar, Sarro-Ramirez Andrea, Arankowsky-Sandoval Gloria and Murillo-Rodriguez Eric, Intrahypothalamic Administration of Modafinil Increases Expression of MAP-Kinase in Hypothalamus and Pons in Rats, CNS & Neurological Disorders - Drug Targets 2015; 14 (4) . https://dx.doi.org/10.2174/1871527314666150429113609
DOI https://dx.doi.org/10.2174/1871527314666150429113609 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epigenetic Interventions Increase the Radiation Sensitivity of Cancer Cells
Current Pharmaceutical Design Alteration of Ceramide 1-O-Functionalization as a Promising Approach for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
Current Cancer Drug Targets Small Molecules Targeting p53 to Improve Antitumor Therapy
Mini-Reviews in Medicinal Chemistry Pharmacological Overview and Future Perspectives of Cholinergic Therapy in Alzheimers Disease
Current Drug Therapy Cell Death Targets and Potential Modulators in Alzheimers Disease
Current Pharmaceutical Design Neuronal Nicotinic Receptors and Neuroprotection: Newer Ligands May Help us Understand their Role in Neurodegeneration
Medicinal Chemistry Reviews - Online (Discontinued) Mechanism of CNS Drugs and their Combinations for Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer
Current Protein & Peptide Science Treatment of Alzheimer's Disease: Classical Therapeutic Approach
Current Pharmaceutical Analysis Extracellular Citrate in Health and Disease
Current Molecular Medicine Protective Effects of Isothiocyanates against Alzheimer's Disease
Current Traditional Medicine The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer
Current Pharmaceutical Design Dual Roles of Sulforaphane in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Induction of Cytoprotective Genes Through Nrf2 / Antioxidant Response Element Pathway: A New Therapeutic Approach for the Treatment of Inflammatory Diseases
Current Pharmaceutical Design Metabolic Aspects of Prion Diseases: An Overview
Current Drug Targets Inhibitory Effect of Ebselen on Cerebral Acetylcholinesterase Activity In Vitro: Kinetics and Reversibility of Inhibition
Current Pharmaceutical Design Solubility Enhancement and Delivery Systems of Curcumin a Herbal Medicine: A Review
Current Drug Delivery Dexamethasone Reduces Cell Adhesion and Migration of T47D Breast Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry